Leerink Partnrs Issues Negative Outlook for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research report issued on Wednesday, June 11th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings per share of $7.71 for the quarter, down from their previous estimate of $8.22. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q3 2025 earnings at $8.77 EPS, Q4 2025 earnings at $8.71 EPS, FY2025 earnings at $31.40 EPS and FY2026 earnings at $32.49 EPS.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 earnings per share.

REGN has been the topic of a number of other research reports. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research note on Thursday, April 17th. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 target price on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $522.68 on Monday. The company has a market capitalization of $56.43 billion, a P/E ratio of 13.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $1,211.20. The business has a 50-day simple moving average of $562.50 and a two-hundred day simple moving average of $646.92.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. Regeneron Pharmaceuticals’s payout ratio is presently 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently modified their holdings of the business. Pinney & Scofield Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 31 shares during the period. Activest Wealth Management lifted its holdings in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC purchased a new stake in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Finally, Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.